WO1999056770A3 - Novel therapy for treatment of lysosomal storage disease - Google Patents

Novel therapy for treatment of lysosomal storage disease Download PDF

Info

Publication number
WO1999056770A3
WO1999056770A3 PCT/CA1999/000368 CA9900368W WO9956770A3 WO 1999056770 A3 WO1999056770 A3 WO 1999056770A3 CA 9900368 W CA9900368 W CA 9900368W WO 9956770 A3 WO9956770 A3 WO 9956770A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
lysosomal storage
storage disease
novel therapy
disease
Prior art date
Application number
PCT/CA1999/000368
Other languages
French (fr)
Other versions
WO1999056770A2 (en
Inventor
Patricia L Chang
Colin J D Ross
Martin R Ralph
Original Assignee
Patricia L Chang
Colin J D Ross
Martin R Ralph
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patricia L Chang, Colin J D Ross, Martin R Ralph filed Critical Patricia L Chang
Priority to AU35141/99A priority Critical patent/AU3514199A/en
Publication of WO1999056770A2 publication Critical patent/WO1999056770A2/en
Publication of WO1999056770A3 publication Critical patent/WO1999056770A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A method for treating or preventing a neurological disease, where the disease is characterized by deficiency of a factor, comprising administering to the CNS of an animal in need thereof, an effective amount of microcapsules which deliver the deficient factor.
PCT/CA1999/000368 1998-05-06 1999-05-06 Novel therapy for treatment of lysosomal storage disease WO1999056770A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU35141/99A AU3514199A (en) 1998-05-06 1999-05-06 Novel therapy for treatment of lysosomal storage disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002236989A CA2236989A1 (en) 1998-05-06 1998-05-06 Novel therapy for treatment of lysosomal storage disease
CA2,236,989 1998-05-06

Publications (2)

Publication Number Publication Date
WO1999056770A2 WO1999056770A2 (en) 1999-11-11
WO1999056770A3 true WO1999056770A3 (en) 2000-01-13

Family

ID=4162400

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1999/000368 WO1999056770A2 (en) 1998-05-06 1999-05-06 Novel therapy for treatment of lysosomal storage disease

Country Status (3)

Country Link
AU (1) AU3514199A (en)
CA (1) CA2236989A1 (en)
WO (1) WO1999056770A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2272482T3 (en) 2000-01-20 2007-05-01 Diabcell Pty Limited PREPARATION AND XENOTRANSPLANT OF SWINE ISLOTS.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543391A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543391A (en) * 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHANG P L: "Microcapsules as bio-organs for somatic gene therapy.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1997 DEC 31) 831 461-73, XP002122346 *
OHASHI T ET AL: "Adenovirus-mediated gene transfer and expression of human beta- glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 FEB 18) 94 (4) 1287-92., XP002122348 *
PEIRONE M A ET AL: "Delivery of recombinant gene product to canines with nonautologous microencapsulated cells.", HUMAN GENE THERAPY, (1998 JAN 20) 9 (2) 195-206., XP002122347 *

Also Published As

Publication number Publication date
AU3514199A (en) 1999-11-23
CA2236989A1 (en) 1999-11-06
WO1999056770A2 (en) 1999-11-11

Similar Documents

Publication Publication Date Title
WO2001030381A3 (en) Use of csf-1 inhibitors
WO2002053101A3 (en) Method for treating fibrotic diseases or other indications
CA2168963A1 (en) Drug for prevention and therapy of diseases caused by fibrinoid formation or thrombus formation in the lung and model animals of the diseases
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
ES2166381T3 (en) TREATMENT OF HYPERPROLIFERATIVE VASCULAR DISEASES.
CY2436B1 (en) Medicament for treating cardiac inflammatory disease.
CA2272584A1 (en) Novel substituted pyrazole derivatives for the treatment of cardiocirculatory diseases
PT1083899E (en) Derivatives of 1-deoxy-galactonojirimycin and their use in the treatment of lysosomal storage diseases by enhancing lysosomal alpha-galactosidase a
ZA9711279B (en) Method for treating and preventing neurological disorders and promoting wound healing.
BG105643A (en) Carboxylic acids and carboxylic acid isosteres of n-heterocycle compounds
WO2001028491A3 (en) Method and composition for the treatment of dermatologic diseases
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
AU8091787A (en) The use of paroxetine to treat pain
MXPA02004747A (en) Hyperoncotic artificial cerebrospinal fluid and method of treating neural tissue edema therewith.
WO2000001668A3 (en) Naaladase inhibitors useful as pharmaceutical compounds and compositions
WO2001024783A3 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence
IT1290781B1 (en) ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES.
WO2002062327A3 (en) Method of treating neurological disorders using acetone derivatives
GB2355196B (en) Companion animal therapeutic treat
WO1999056770A3 (en) Novel therapy for treatment of lysosomal storage disease
MY122052A (en) Method of treating tourette''s syndrome
EP1056458A4 (en) Method for the treatment of pain, including chronic and female specific pain
WO2001015710A3 (en) A method of treatment of human immunodeficiency diseases
WO2000059940A3 (en) Platelet-derived growth factor related gene and protein

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: KR

NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase